[Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].

Zyryanov, S K; Avdeev, S N; Ivanov, D A; Zhuravleva, M V; Kniajeskaia, N P; Matveev, N V; Nenasheva, N A; Fomina, D S; Frolov, M I

Zyryanov, S K; Avdeev, S N; Ivanov, D A; Zhuravleva, M V; Kniajeskaia, N P; Matveev, N V; Nenasheva, N A; Fomina, D S; Frolov, M I.

Afiliação

Zyryanov SK; People's Friendship University of Russia.
Avdeev SN; City Clinical Hospital â24.
Ivanov DA; Sechenov First Moscow State Medical University (Sechenov University).
Zhuravleva MV; Research Institute of Pulmonology.
Kniajeskaia NP; People's Friendship University of Russia.
Matveev NV; Sechenov First Moscow State Medical University (Sechenov University).
Nenasheva NA; Scientific Centre for Expert Evaluation of Medicinal Products.
Fomina DS; Pirogov Russian National Research Medical University.
Frolov MI; Pirogov Russian National Research Medical University.

Ter Arkh ; 92(12): 172-179, 2020 Dec 15.

Article em Ru | MEDLINE | ID: mdl-33720591

Assuntos

Antiasmáticos; Asma; Adulto; Antiasmáticos/uso terapêutico; Anticorpos Monoclonais Humanizados; Asma/tratamento farmacológico; Humanos; Federação Russa

Palavras-chave

benralizumab; disease-related groups; eosinophilic asthma; mepolizumab; pharmacoeconomic study; regions of Russia; reslizumab; severe asthma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos Tipo de estudo: Health_economic_evaluation Limite: Adult / Humans País como assunto: Asia / Europa Idioma: Ru Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google